Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026

Same author

Longitudinal <sup>1</sup>H and <sup>129</sup>Xe Lung MRI in Patients With Post-COVID Residual Lung Abnormalities.

Journal of magnetic resonance imaging : JMRI·2026

Same author

Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.

ERJ open research·2026

Same author

Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.

Research square·2026

Same author

Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS study.

BMJ open respiratory research·2026

Same author

BAL cells analysis and lung function parameters in fibrotic hypersensitivity pneumonitis at baseline and in relation to survival.

Respiratory investigation·2026

Same journal

Beyond the High: A Narrative Review of the Chronic Complications of Recreational Ketamine Use.

British journal of hospital medicine (London, England : 2005)·2026

Same journal

Prolonged Undiagnosed Prodromal Symptoms.

British journal of hospital medicine (London, England : 2005)·2026

Same journal

Human Factors and Deterioration: What Success Factors Facilitate Escalation of Care and How Can These Be Applied More Reliably?

British journal of hospital medicine (London, England : 2005)·2026

Same journal

Comparative Evaluation of Functional Outcomes and Postoperative Complications After Minimally Invasive Fixation for Acromioclavicular Joint Injuries.

British journal of hospital medicine (London, England : 2005)·2026

Same journal

A Systematic Review of Functional MRI Studies on Seasonal Modulation of Brain Functional Connectivity.

British journal of hospital medicine (London, England : 2005)·2026

Same journal

More Than Myocarditis? Cardiac Involvement in Phaeochromocytoma-A Case Report.

British journal of hospital medicine (London, England : 2005)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 1, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Idiopathic Pulmonary Fibrosis: An Overview.

James May¹, Gisli Jenkins¹

¹Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, SW3 6LY London, UK.

British Journal of Hospital Medicine (London, England : 2005)

|February 28, 2026

Summary

This summary is machine-generated.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatments. Research aims to improve understanding and management of IPF, offering hope for better therapies and patient outcomes.

Keywords:

diagnosis idiopathic pulmonary fibrosis management outcomes risk factors

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Mar 1, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Area of Science:

Pulmonology and Respiratory Medicine
Pathobiology of Fibrotic Diseases
Translational Medicine

Background:

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a rising incidence and poor prognosis.
Current treatments for IPF only slow disease progression, highlighting a significant unmet medical need.
Lung transplantation offers the only substantial improvement in survival and quality of life for IPF patients.

Purpose of the Study:

To provide a comprehensive overview of Idiopathic Pulmonary Fibrosis (IPF).
To summarize current knowledge on IPF definitions, epidemiology, pathobiology, diagnostics, and management strategies.
To highlight the limitations of existing therapies and the need for novel treatments.

Main Methods:

Literature review and synthesis of existing research on IPF.
Analysis of epidemiological data and disease incidence trends.
Summary of current diagnostic criteria and management guidelines for IPF.

Main Results:

IPF is characterized by relentless progression, leading to debilitating dyspnea and respiratory failure.
Average survival post-diagnosis is 3-5 years, underscoring the disease's severity.
Despite advances in understanding IPF pathobiology, therapeutic options remain limited.

Conclusions:

There is an urgent need for therapies that can halt or reverse fibrosis in IPF.
Ongoing research into new therapeutic approaches shows promise for improving IPF outcomes.
A comprehensive understanding of IPF is crucial for advancing diagnostic and management strategies.